Multiple Grain in Type 2 Diabetes

National Cheng-Kung University

Status and phase

Unknown

Phase 4

Conditions

Diabetes Mellitus

Treatments

Behavioral: Ordinary Asian- rice

Behavioral: Multiple grain

Study type

Interventional

Funder types

Other

Identifiers

NCT00337337

NCKU-94-032

Details and patient eligibility

About

We aim to investigate the beneficial effect of adding grain fiber to daily rice meal in type 2 diabetic patients. We anticipate this intervention will improve glycemia and lipid profile in these patients.

Full description

Resistance of insulin-mediated glucose transport is a fundamental early defect in the pathogenesis of type 2 diabetes mellitus (DM). It has been found that high fiber concentration in meal is frequently associated with low GI. In many single-blind cross-over study, short term consumption of high fiber meal has been shown to enhance postprandial insulin sensitivity in healthy subjects. We presume that increasing daily consumption of fiber would improve the insulin resistance and therefor glycemic parameters patients with DM. Patients with type 2 diabetes with stable dose of hypoglycemic medication control will be recruited, two types of meals will be given, type A is a general Asian rice-meal and type B consists of the same rice with multiple-grain-fiber added. Both type of meals will be consumed for 3 months by each patients.

Sex

All

Ages

25 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Mentally competent adults of either sex with age 30-75 years old
Patients have type 2 diabetes mellitus diagnosed after 25 years of age
Patients have been in inadequate but stable glycemic control by diet. Inadequate glycemic control isdefined as: HbA1c 7.1-11.0%
Patients have signed the written informed consent.

Exclusion criteria

Patients with type 1 diabetes mellitus
Patients with alcohol, drugs or medications abuse considered by the investigator
Patients with impaired liver function (AST, ALT>2.5× upper limit of normal)
Patients with impaired kidney function (serum creatinine>3.0 mg/dl)
Patients with emphysema or chronic bronchitis
Patients with hepatic cirrhosis
Patients with chronic intestinal diseases related to marked disorders of digestion or absorption
Patients participated investigational drug trial within 1 month before entering this study
Patients with any other serious diseases considered by the investigator not in the condition to enter the trial